Cargando…
Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
OBJECTIVE: The aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients. METHODS: Seventy-six patients with c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899895/ https://www.ncbi.nlm.nih.gov/pubmed/36756119 http://dx.doi.org/10.3389/fimmu.2023.1121778 |
_version_ | 1784882732259606528 |
---|---|
author | Wang, Wen-Xin Jia, Rui Jin, Xue-Yuan Li, Xiaoyan Zhou, Shuang-Nan Zhang, Xiao-Ning Zhou, Chun-Bao Wang, Fu-Sheng Fu, Junliang |
author_facet | Wang, Wen-Xin Jia, Rui Jin, Xue-Yuan Li, Xiaoyan Zhou, Shuang-Nan Zhang, Xiao-Ning Zhou, Chun-Bao Wang, Fu-Sheng Fu, Junliang |
author_sort | Wang, Wen-Xin |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients. METHODS: Seventy-six patients with chronic hepatitis B with HBsAg less than 1,500 IU/ml and HBV DNA negative after receiving ≥ 1-year NAs therapy were enrolled. Eighteen patients continued to take NAs monotherapy (the NAs group), and 58 patients received combination therapy with NAs and PEG-IFN-α (the Add-on group). The levels of IFNG, IL1B, IL1RN, IL2, IL4, IL6, IL10, IL12A, IL17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF, and CSF2 in peripheral blood during treatment were detected. RESULTS: At week 48, 0.00% (0/18) in the NAs group and 25.86% (15/58) in the Add-on group achieved HBsAg loss. During 48 weeks of combined treatment, there was a transitory increase in the levels of ALT, IL1RN, IL2, and CCL2. Compared to the NAs group, CXCL8 and CXCL10 in the Add-on group remain higher after rising, yet CCL3 showed a continuously increasing trend. Mild and early increases in IL1B, CCL3, IL17A, IL2, IL4, IL6, and CXCL8 were associated with HBsAg loss or decrease >1 log, while sustained high levels of CCL5 and CXCL10 were associated with poor responses to Add-on therapy at week 48. CONCLUSIONS: The serum cytokine change profile is closely related to the response to the combination therapy with PEG-IFN-α and NAs, and may help to reveal the mechanism of functional cure and discover new immunological predictors and new therapeutic targets. |
format | Online Article Text |
id | pubmed-9899895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98998952023-02-07 Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients Wang, Wen-Xin Jia, Rui Jin, Xue-Yuan Li, Xiaoyan Zhou, Shuang-Nan Zhang, Xiao-Ning Zhou, Chun-Bao Wang, Fu-Sheng Fu, Junliang Front Immunol Immunology OBJECTIVE: The aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients. METHODS: Seventy-six patients with chronic hepatitis B with HBsAg less than 1,500 IU/ml and HBV DNA negative after receiving ≥ 1-year NAs therapy were enrolled. Eighteen patients continued to take NAs monotherapy (the NAs group), and 58 patients received combination therapy with NAs and PEG-IFN-α (the Add-on group). The levels of IFNG, IL1B, IL1RN, IL2, IL4, IL6, IL10, IL12A, IL17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF, and CSF2 in peripheral blood during treatment were detected. RESULTS: At week 48, 0.00% (0/18) in the NAs group and 25.86% (15/58) in the Add-on group achieved HBsAg loss. During 48 weeks of combined treatment, there was a transitory increase in the levels of ALT, IL1RN, IL2, and CCL2. Compared to the NAs group, CXCL8 and CXCL10 in the Add-on group remain higher after rising, yet CCL3 showed a continuously increasing trend. Mild and early increases in IL1B, CCL3, IL17A, IL2, IL4, IL6, and CXCL8 were associated with HBsAg loss or decrease >1 log, while sustained high levels of CCL5 and CXCL10 were associated with poor responses to Add-on therapy at week 48. CONCLUSIONS: The serum cytokine change profile is closely related to the response to the combination therapy with PEG-IFN-α and NAs, and may help to reveal the mechanism of functional cure and discover new immunological predictors and new therapeutic targets. Frontiers Media S.A. 2023-01-23 /pmc/articles/PMC9899895/ /pubmed/36756119 http://dx.doi.org/10.3389/fimmu.2023.1121778 Text en Copyright © 2023 Wang, Jia, Jin, Li, Zhou, Zhang, Zhou, Wang and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Wen-Xin Jia, Rui Jin, Xue-Yuan Li, Xiaoyan Zhou, Shuang-Nan Zhang, Xiao-Ning Zhou, Chun-Bao Wang, Fu-Sheng Fu, Junliang Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
title | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
title_full | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
title_fullStr | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
title_full_unstemmed | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
title_short | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
title_sort | serum cytokine change profile associated with hbsag loss during combination therapy with peg-ifn-α in nas-suppressed chronic hepatitis b patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899895/ https://www.ncbi.nlm.nih.gov/pubmed/36756119 http://dx.doi.org/10.3389/fimmu.2023.1121778 |
work_keys_str_mv | AT wangwenxin serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT jiarui serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT jinxueyuan serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT lixiaoyan serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT zhoushuangnan serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT zhangxiaoning serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT zhouchunbao serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT wangfusheng serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT fujunliang serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients |